News - Novo Nordisk

Filter

Current filters:

Novo Nordisk

Popular Filters

100 to 124 of 130 results

FDA OKs pregnancy use of Novo Nordisk diabetes therapy Levemir

02-04-2012

The US Food and Drug Administration has approved Levemir (insulin detemir [rDNA origin] injection), from…

DiabetesLevemirNorth AmericaNovo NordiskPharmaceuticalRegulation

Pfizer and Biocon cancel biosimilars deal

14-03-2012

Indian biotech firm Biocon (BSE: 532523) and global drugs behemoth Pfizer (NYSE: PFE) yesterday announced…

Asia-PacificBioconBiotechnologyDiabetesInsulinLicensingNovo NordiskPfizerPharmaceutical

Victoza sales boost Novo Nordisk

03-02-2012

Danish insulin giant Novo Nordisk (NVO: N) yesterday reported full-year 2011 sales of 66.35 billion Danish…

DiabetesFinancialNovo NordiskPharmaceuticalVictoza

Novo Nordisk opens type 1 diabetes R&D center in Seattle

24-01-2012

Danish insulin giant Novo Nordisk (NVO: N) said this morning that it will establish a type 1 diabetes…

DiabetesNovo NordiskPharmaceuticalResearch

Lundbeck submits Selincro in EU; Novo Nordisk files Degludec in Japan

22-12-2011

Danish CNS drug specialist Lundbeck (LUND: DC) revealed yesterday that it has submitted a marketing authorization…

Asia-PacificBiotie TherapiesDegludecDiabetesEuropeLundbeckNeurologicalNovo NordiskPharmaceuticalRegulationSelincro

Novo Nordisk reaches a milestone in stopping animal testing

29-11-2011

Danish insulin giant Novo Nordisk (NVO: N) has released a video highlighting that, effective yesterday…

DiabetesNovo NordiskPharmaceuticalRegulationResearch

Denmark’s Novo Nordisk partners to tackle Qatar’s diabetes problem

24-11-2011

According to Danish insulin giant Novo Nordisk (NVO: N) diabetes is on the rise in Qatar and poses a…

DiabetesHealthcareNovo NordiskPharmaceuticalRest of the World

GlaxoSmithKline’s albiglutide fails to show superiority over Novo Nordisk’s Victoza

18-11-2011

UK pharma giant GlaxoSmithKline (LSE: GSK) released disappointing top-line results from the first of…

albiglutideDiabetesGlaxoSmithKlineNovo NordiskPharmaceuticalResearchVictoza

Novo Nordisk says DegludecPlus provides superior glycemic control vs Lantus

07-11-2011

Denmark-based insulin giant Novo Nordisk (NVO: N) yesterday announced positive clinical results from…

DegludecDegludecPlusDiabetesLantusNovo NordiskPharmaceuticalResearchSanofi

EU OKs two new indications for Novo Nordisk’s Levemir

03-11-2011

There was good news for Danish insulin giant Novo Nordisk (NVO: N) yesterday, when the European Commission…

DiabetesEuropeLevemirNovo NordiskPharmaceuticalRegulationVictoza

Modern insulins and Victoza drive 8% nine-month sales rise at Novo Nordisk

28-10-2011

Danish insulin giant Novo Nordisk (NVO: N) has reported financial results for the first nine months of…

DiabetesFinancialNovo NordiskPharmaceutical

AstraZeneca to investment $200 million in Chinese manufacturing plant; Novo Nordisk debuts Victoza

10-10-2011

Anglo-Swedish drug major AstraZeneca ILSE: AZN) said this morning that it is investing $200 million in…

Asia-PacificAstraZenecaDiabetesFinancialMarkets & MarketingNovo NordiskPharmaceuticalRegulationVictoza

Novo Nordisk files for EU approval of ultra-long-acting insulins Degludec and DegludecPlus

28-09-2011

Danish insulin giant Novo Nordisk NVO: N) has made the first regulatory approval submissions, to the…

DegludecDiabetesEuropeNovo NordiskPharmaceuticalRegulation

Obesity drug market set to grow to $2.6 billion by 2020, says DR report

27-09-2011

The obesity drug market will increase more than six-fold over the next decade, increasing from $420 million…

Arena PharmaceuticalsContraveLorqessMarkets & MarketingMetabolicsNovo NordiskOrexigen TherapeuticsPharmaceuticalQnexaVictozaVivus

High demand for monoclonal antibodies will drive therapeutic proteins market

22-09-2011

The global therapeutic proteins market will grow at a moderate pace, with monoclonal antibodies considered…

AmgenBiotechnologyGlobalMarkets & MarketingNovo NordiskPharmaceuticalRoche

Data show Novo Nordisk’s ultra-long-acting insulin degludec can be flexibly dosed

15-09-2011

Danish insulin giant Novo Nordisk’s (NVO: N) ultra-long-acting insulin degludec, an investigational…

DegludecDiabetesNovo NordiskPharmaceuticalResearch

Strong new data on Novo Nordisk’s Victoza and Lilly/Amylin’s Bydureon presented at EADS

13-09-2011

A significantly higher proportion of patients reached the target for blood sugar control (HbA1c target…

AlkermesAmylinBydureonDiabetesEli LillyNovo NordiskPharmaceuticalResearchVictoza

Senior appointments at Novo Nordisk and Sucampo

08-09-2011

The US unit of Danish insulin giant Novo Nordisk (NVO: N) has appointed Eddie Li, as vice president,…

ManagementNovo NordiskPharmaceuticalSucampo

Novo Nordisk extends free insulin and diabetes care program to India

07-09-2011

Denmark’s Novo Nordisk (NVO: N), the world’s largest insulin maker, yesterday launched its…

Asia-PacificDiabetesMarkets & MarketingNovo NordiskPharmaceutical

Novo Nordisk first-half 2011 sales and profit leap

04-08-2011

Danish insulin giant Novo Nordisk (NVO: N) posted first-half 2011 sales of 31.69 billion Danish kroner…

DiabetesFinancialNovo NordiskPharmaceuticalVictoza

European Commission and Australia OK Bristol-Myers Yervoy and Novo Nordisk’s FlexTouch

15-07-2011

Following a recent positive recommendation from the European Medicine Agency’s advisory panel, Bristol-Myers…

Bristol-Myers SquibbDiabetesEuropeFlexTouchNovo NordiskOncologyPharmaceuticalRegulationYervoy

100 to 124 of 130 results

Company Spotlight

Fibrotech

Fibrotech

Back to top